PTPN11 and chordoma: Consistent with the RMC-4550 study, statistically significant antitumor efficacy was achieved in the U-CH1 mouse model treated with 20 mg/kg of TNO155 (P = 1.27 × 10−6), a clinical-stage SHP2 inhibitor with ex vivo anti-chordoma activity comparable to that of RMC-4550 and SHP099 (Fig. 5d and Supplementary Figs. 12,,  13).